PT2367542E - Formas de dosagem oral de bendamustina - Google Patents

Formas de dosagem oral de bendamustina Download PDF

Info

Publication number
PT2367542E
PT2367542E PT97963037T PT09796303T PT2367542E PT 2367542 E PT2367542 E PT 2367542E PT 97963037 T PT97963037 T PT 97963037T PT 09796303 T PT09796303 T PT 09796303T PT 2367542 E PT2367542 E PT 2367542E
Authority
PT
Portugal
Prior art keywords
bendamustine
dosage forms
oral dosage
oral
forms
Prior art date
Application number
PT97963037T
Other languages
English (en)
Inventor
Jeffrey Colledge
Margaretha Olthoff
Original Assignee
Astellas Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40588059&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT2367542(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Deutschland Gmbh filed Critical Astellas Deutschland Gmbh
Publication of PT2367542E publication Critical patent/PT2367542E/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0053Mouth and digestive tract, i.e. intraoral and peroral administration
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816Wall or shell material
    • A61K9/4825Proteins, e.g. gelatin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/485Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4858Organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4875Compounds of unknown constitution, e.g. material from plants or animals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Botany (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PT97963037T 2008-12-03 2009-12-03 Formas de dosagem oral de bendamustina PT2367542E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08075915 2008-12-03

Publications (1)

Publication Number Publication Date
PT2367542E true PT2367542E (pt) 2014-03-10

Family

ID=40588059

Family Applications (1)

Application Number Title Priority Date Filing Date
PT97963037T PT2367542E (pt) 2008-12-03 2009-12-03 Formas de dosagem oral de bendamustina

Country Status (25)

Country Link
US (4) US20120003305A1 (pt)
EP (1) EP2367542B1 (pt)
JP (1) JP5778037B2 (pt)
KR (1) KR101688038B1 (pt)
CN (2) CN105363037B (pt)
AU (1) AU2009321745B2 (pt)
BR (1) BRPI0922806B8 (pt)
CA (1) CA2745525A1 (pt)
CO (1) CO6400183A2 (pt)
CY (1) CY1114977T1 (pt)
DK (1) DK2367542T3 (pt)
EA (1) EA020354B1 (pt)
ES (1) ES2451540T3 (pt)
HR (1) HRP20140204T1 (pt)
IL (1) IL213270A (pt)
MX (1) MX2011005643A (pt)
NZ (1) NZ592970A (pt)
PL (1) PL2367542T3 (pt)
PT (1) PT2367542E (pt)
RS (1) RS53201B (pt)
SI (1) SI2367542T1 (pt)
SM (1) SMT201400053B (pt)
UA (1) UA102120C2 (pt)
WO (1) WO2010063493A1 (pt)
ZA (1) ZA201103791B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2575784T3 (en) 2010-06-02 2018-10-15 Astellas Deutschland Gmbh ORAL DOSAGE FORMS OF BENDAMUSTIN
JO3659B1 (ar) * 2010-06-02 2020-08-27 Astellas Deutschland Gmbh أشكال جرعات بينداموستين عن طريق الفم وإستخداماته العلاجية
CN102375044B (zh) * 2010-08-18 2015-04-08 重庆华邦胜凯制药有限公司 一种盐酸苯达莫司汀中间体z6有关物质的分析方法
WO2013046223A1 (en) * 2011-09-26 2013-04-04 Fresenius Kabi Oncology Ltd. An improved process for the preparation of bendamustine hydrochloride
CN108704132A (zh) 2011-10-31 2018-10-26 弗·哈夫曼-拉罗切有限公司 抗体制剂
EP2641592A1 (en) 2012-03-23 2013-09-25 Salmon Pharma GmbH Pharmaceutical formulation comprising bendamustine
ES2535511T3 (es) 2012-04-26 2015-05-12 Helmut Schickaneder Ésteres de bendamustina y compuestos relacionados, y uso médico de los mismos
EP2917183A1 (en) * 2012-11-12 2015-09-16 Ignyta, Inc. Bendamustine derivatives and methods of using same
US9598377B2 (en) 2013-03-12 2017-03-21 Cephalon, Inc. Nanoparticulate and macroparticulate formulations
JP2016153374A (ja) * 2013-06-25 2016-08-25 シンバイオ製薬株式会社 炎症性疾患を治療又は予防するための医薬組成物
EP3043648B1 (en) 2013-08-27 2023-09-20 Vasilios VOUDOURIS Bendamustine pharmaceutical compositions
CN111201019A (zh) 2017-10-05 2020-05-26 图贝药物有限公司 口服苯达莫司汀制剂

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US132502A (en) * 1872-10-22 Improvement in machines for removing snow from railroads
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US20030105141A1 (en) * 2001-04-17 2003-06-05 Ping Gao Finely self-emulsifiable pharmaceutical composition
US20040048931A1 (en) * 2002-07-12 2004-03-11 Craig Heacock Modafinil pharmaceutical compositions
US20060128777A1 (en) 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
CN101052396A (zh) * 2004-11-05 2007-10-10 赛福伦公司 癌症治疗
UA94036C2 (ru) * 2005-01-14 2011-04-11 Сефалон, Инк. Фармацевтическая композиция бендамустина, предназначенная для лиофилизации
US8436190B2 (en) * 2005-01-14 2013-05-07 Cephalon, Inc. Bendamustine pharmaceutical compositions
CN101028249A (zh) * 2007-04-12 2007-09-05 济南康泉医药科技有限公司 一种含新生血管抑制剂及烷化剂的抗癌组合物
CN101045058A (zh) * 2007-04-28 2007-10-03 济南帅华医药科技有限公司 一种含烷化剂及激素类药物的抗癌组合物
CN101084876A (zh) * 2007-07-11 2007-12-12 济南康泉医药科技有限公司 一种含苯达莫司汀的抗癌组合物
US20090130198A1 (en) * 2007-11-21 2009-05-21 Innopharmax Inc. Pharmaceutical composition with enhanced bioavailability
US8349353B2 (en) * 2008-06-27 2013-01-08 Otonomy, Inc. Controlled release cytotoxic agent compositions and methods for the treatment of otic disorders

Also Published As

Publication number Publication date
US20120003305A1 (en) 2012-01-05
NZ592970A (en) 2013-05-31
PL2367542T3 (pl) 2014-05-30
EP2367542A1 (en) 2011-09-28
CA2745525A1 (en) 2010-06-10
US20170095452A1 (en) 2017-04-06
HRP20140204T1 (hr) 2014-04-11
MX2011005643A (es) 2011-09-27
KR20110102393A (ko) 2011-09-16
AU2009321745A1 (en) 2011-06-23
JP5778037B2 (ja) 2015-09-16
IL213270A0 (en) 2011-07-31
EP2367542B1 (en) 2014-01-01
CY1114977T1 (el) 2016-12-14
BRPI0922806A2 (pt) 2015-12-22
UA102120C2 (ru) 2013-06-10
SI2367542T1 (sl) 2014-05-30
WO2010063493A1 (en) 2010-06-10
BRPI0922806B8 (pt) 2021-05-25
EA201190011A1 (ru) 2012-02-28
ZA201103791B (en) 2012-07-25
US20150335588A1 (en) 2015-11-26
KR101688038B1 (ko) 2016-12-20
RS53201B (en) 2014-06-30
BRPI0922806B1 (pt) 2020-03-03
CN105363037A (zh) 2016-03-02
US20140018334A1 (en) 2014-01-16
JP2012510484A (ja) 2012-05-10
IL213270A (en) 2017-05-29
AU2009321745B2 (en) 2016-06-23
CN105363037B (zh) 2019-02-05
ES2451540T3 (es) 2014-03-27
CN102281871A (zh) 2011-12-14
CO6400183A2 (es) 2012-03-15
EA020354B1 (ru) 2014-10-30
SMT201400053B (it) 2014-07-07
US10543196B2 (en) 2020-01-28
DK2367542T3 (da) 2014-03-10

Similar Documents

Publication Publication Date Title
HRP20171421T1 (hr) Kruti oblici doziranja bendamustina
HK1220966A1 (zh) 鹽酸苯達莫司汀固體形式
IL213270A0 (en) Oral dosage forms of bendamustine
IL214628A0 (en) Sustained release oral dosage forms of an r- baclofen prodrug
HK1253541A1 (zh) 使用澱粉的口服疫苗快速溶解劑型
EP2563346A4 (en) SOLID ORAL PHARMACEUTICAL FORMS WITH TADALAFIL
HK1154484A1 (en) Oral dosage composition
PL2173345T3 (pl) Doustna formulacja metadoksyny
GB0710439D0 (en) Oral dosage form
IL210235A0 (en) Oral formulation
IL223311A0 (en) Oral dosage forms of bendamustine
EP2435052A4 (en) SOLID PHARMACEUTICAL FORMS OF LAMIVUDIN ORAL ADMINISTRATION
IL245577A0 (en) Dose unit of efdanosone
GB0822124D0 (en) Oral dosage form
HK1131039A1 (en) Pharmaceutical use of sophoricoside
IL219860A0 (en) Oral formulation for dexlansoprazole
GB0906003D0 (en) Oral drug formulation
GB201018760D0 (en) An oral dosage form